Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision Inc. (VTAK) delivers innovative electrophysiology solutions through its VIVO cardiac mapping system and LockeT vascular closure technology. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments in non-invasive cardiac care.
Investors and medical professionals will find curated press releases covering regulatory milestones, product innovations, and partnership agreements. Our repository includes updates on FDA clearances, international distribution expansions, and peer-reviewed study results validating device efficacy.
Key content categories include quarterly financial results, technology enhancements to the VIVO 3D imaging platform, and clinical outcomes data for the suture retention system. All materials maintain compliance with financial disclosure regulations while emphasizing patient-centered innovation in arrhythmia treatment.
Bookmark this page for real-time updates on Catheter Precision's advancements in electrophysiology and vascular closure solutions. Visit regularly to stay informed about developments impacting cardiac care technology and investment considerations.
Catheter Precision (VTAK) announced its participation in the 46th annual Heart Rhythm Society (HRS) meeting from April 24-27, 2025, in San Diego. The conference will gather nearly 10,000 professionals in arrhythmia care and electrophysiology, featuring over 200 educational sessions and 3,400 scientific abstracts.
The company will present four research abstracts at HRS 2025: three for VIVO and one for LockeT. Key findings include:
- VIVO showed 94% accuracy in a 125 multi-center European study with 83% long-term procedural success
- Research demonstrating VIVO's effectiveness in mapping difficult-to-identify PVCs
- LockeT's safety and efficacy study in 139 patients for large-bore access procedures
- VIVO's 89% accuracy in predicting exit site locations for scar-dependent VT, with 86% of patients free from device therapy after one year
Catheter Precision (VTAK) has signed a definitive agreement to acquire assets related to the Cardiac Pulmonary Nerve Stimulation (CPNS) System through its 82% owned subsidiary, Cardionomix. The CPNS System, developed by Cardionomic, targets acute decompensated heart failure (ADHF) treatment through electrical stimulation via a temporary catheter.
The acquisition terms include 1,000,000 unregistered common stock shares and a $1.5 million three-year promissory note at 4% annual interest through Cardionomix. Initial clinical studies showed promising results, including reduced heart failure worsening, increased fluid loss, improved quality of life, and reduced mortality.
The technology addresses a market of approximately 1 million annual U.S. hospital admissions for heart failure, with potential annual revenues exceeding $1 billion. The Cleveland Clinic Foundation, Abbott Laboratories, and New Era Associates will receive economic interests in VTAK common stock and Cardionomix note as current creditors.
Catheter Precision (NYSE: VTAK), a US medical device company specializing in cardiac electrophysiology products, has made a mandatory public announcement under NYSE American Company Guide Section 610(b). The company disclosed that its audited financial statements for the year ended December 31, 2024, included an independent audit opinion containing a Substantial Doubt Regarding Going Concern paragraph.
This disclosure, previously included in the company's Annual Report on Form 10-K filed March 31, 2025, does not represent any changes or amendments to the consolidated financial statements or the annual report.
Catheter Precision (NYSE/American: VTAK) has received its first US patent allowance for the LockeT surgical closure device, designed for orthoscopic entry wounds. This adds to the company's existing international patents for LockeT in China, Europe, and the United Kingdom.
The company expects to receive the CE mark for LockeT in the current quarter, which will enable revenue generation in Europe. The product has been well-received since its US rollout in late last year, offering improved outcomes while reducing procedure costs in international markets.
Catheter Precision (NYSE American: VTAK) reported its Q4 and full-year 2024 financial results. The company's Q4 revenue reached $149,000, showing a 55% sequential increase from Q3, while full-year 2024 revenue totaled $420,000. Q4 net loss was $5.6 million, including $3.1 million in non-cash charges, with full-year net loss at $16.6 million.
Key operational highlights include: sequential growth in LockeT sales since Q2 2024, completion of CE Mark audits in Q4 2024 with anticipated approval in Q2 2025, and expansion of VIVO sales across multiple international markets. The company reported 26 institutions evaluating LockeT by year-end. Financial position shows total assets of $27.7 million and shareholders' equity of $11.8 million as of December 31, 2024, with 8,004,633 outstanding common shares.
Catheter Precision (NYSE: VTAK) announced its participation in three major medical conferences through April 2, 2025: the American College of Cardiology (ACC) in Chicago, the European Heart Rhythm Association (EHRA) in Vienna, and the Society of Interventional Radiology (SIR) in Nashville.
At ACC, the company will present a poster abstract showcasing their LockeT device. A recent study of 97 patients demonstrated LockeT's advantages over manual compression for hemostasis, including reduced ambulation time, lower resource utilization, and cost-effectiveness compared to vascular closure devices.
The company will exhibit VIVO at EHRA and LockeT at SIR, marking their first appearance at an interventional radiology conference. CEO David Jenkins emphasized the importance of conference attendance for meeting industry leaders, sharing clinical data, and connecting with new customers.
Catheter Precision (NYSE/American: VTAK) has announced its participation in the 18th Western Atrial Fibrillation Symposium from February 27 – March 1 in Salt Lake City, Utah. The symposium, featuring over 80 world-renowned faculty members, focuses on improving atrial fibrillation (AF) outcomes globally through discussions of latest diagnostic and treatment advancements.
The company aims to showcase its LockeT product line, which serves as an adjunctive solution for atrial fibrillation procedures. CEO David Jenkins emphasized that attending industry-specific meetings is important to their commercialization strategy, with the goal of educating physicians about LockeT's benefits for recovery room staff, hospitals, and patients.
Catheter Precision (NYSE American: VTAK) has engaged PCG Advisory to enhance its investor relations strategy and market communications. The company, which develops cardiac electrophysiology medical devices, aims to strengthen engagement with institutional and retail investors while increasing awareness of its LockeT and VIVO™ technologies.
These innovative devices address challenges in electrophysiology and vascular closure, focusing on improving procedural efficiency and reducing complications. The company is entering its commercial phase, with CEO David Jenkins highlighting the potential of their technologies to deliver value to shareholders and healthcare providers.
The engagement comes as the electrophysiology market is projected to reach $15.1 billion by 2028, driven by increasing demand for ventricular ablation treatments and vascular closure solutions.
Catheter Precision (VTAK) has announced its participation in the 13th International Symposium on Left Atrial Appendage (ISLAA) taking place on February 7th and 8th, 2025, in Austin, Texas. The symposium is a multi-specialty cardiovascular educational event focusing on left atrial appendage science.
The program will be managed by leading physicians from prestigious institutions including The Kansas City Heart Rhythm Institute, Texas Cardiac Arrhythmia Institute, Los Robles Medical Center, Mayo Clinic, and Mt. Sinai. The event features hands-on demonstrations and product education for electrophysiology fellows.
Catheter Precision will showcase LockeT, their solution for closing large access sites after LAA procedures. CEO David Jenkins highlighted that LockeT offers a safe and effective option for wound closure, enabling cost reduction and same-day hospital discharge.
Catheter Precision (NYSE American: VTAK) has successfully completed its previously announced acquisition of PeriKard, . The transaction, which was completed within the anticipated timeline, was structured as an all-stock deal. According to CEO David Jenkins, the acquired technology aligns with the company's focus on the ventricular therapeutic market and is expected to support their growth strategy in this market segment.
FAQ
What is the current stock price of Catheter Precision (VTAK)?
What is the market cap of Catheter Precision (VTAK)?
